Live Breaking News & Updates on Profit Fall

Stay updated with breaking news from Profit fall. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall

Friday, AbbVie Inc (NYSE:ABBV) reported fourth-quarter adjusted EPS of $2.79, down 22.5% Y/Y, beating the consensus of $2.77. Fourth-quarter net revenues reached $14.301 billion, down 5.4% Y/Y, beating the consensus of $14.02 billion. The immunology portfolio generated $6.95 billion in sales, down 12.3%. Humira revenues were $3.30 billion (down 40.8%), Skyrizi sales reached $2.39 billion (up 51.9%), and Rinvoq revenues were $1.26 billion (up 62.9%). Related: Aesthetics Market Resilience: AbbVie ....

Cerevel Therapeutics Holdings Inc , Consumer Group Pushes For Stronger Warnings , Abbvie Inc , Immunogen Inc , Consumer Group Pushes , Global Botox Cosmetic , Cerevel Therapeutics , Stock Market Game , Benzinga Pro , Day Trial , Profit Fall ,